Sign in or create an account to add this stock to your watchlist.
About Syros Pharmaceuticals (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340
Debt
Debt-to-Equity RatioN/A
Current Ratio5.78
Quick Ratio5.78
Price-To-Earnings
Trailing P/E Ratio-5.60
Forward P/E Ratio-5.42
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.10 million
Price / Sales353.34
Cash FlowN/A
Price / CashN/A
Book Value$3.21 per share
Price / Book3.72
Profitability
EPS (Most Recent Fiscal Year)($2.13)
Net Income$-54,010,000.00
Net MarginsN/A
Return on Equity-67.11%
Return on Assets-57.78%
Miscellaneous
Employees56
Outstanding Shares32,580,000
Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions
What is Syros Pharmaceuticals' stock symbol?
Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."
How were Syros Pharmaceuticals' earnings last quarter?
Syros Pharmaceuticals (NASDAQ:SYRS) released its quarterly earnings data on Monday, March, 12th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.01. View Syros Pharmaceuticals' Earnings History.
When is Syros Pharmaceuticals' next earnings date?
What price target have analysts set for SYRS?
8 brokers have issued 12 month price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $33.00. On average, they expect Syros Pharmaceuticals' stock price to reach $22.4286 in the next year. View Analyst Ratings for Syros Pharmaceuticals.
What are Wall Street analysts saying about Syros Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (5/16/2018)
- 2. Cann analysts commented, "For 2018 we have adjusted revenue to account for a $10 million upfront payment being carried on the balance sheet rather than being recognized as revenue this year; and we are fine-tuning estimated operating expenses and estimated shares outstanding. As a result, our estimated loss per share is being increased to $2.04 from our prior estimated loss of $1.81. Our estimated revenue and net income for 2019-22 is unchanged. Estimated loss per share is being increased by $0.01 per year in years 2019 and 2020 as a result of slightly reduced estimated shares outstanding." (5/10/2018)
Who are some of Syros Pharmaceuticals' key competitors?
Some companies that are related to Syros Pharmaceuticals include ARMO BioSciences (ARMO), Zogenix (ZGNX), Innoviva (INVA), PTC Therapeutics (PTCT), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Impax Laboratories (IPXL), TherapeuticsMD (TXMD), Endo International (ENDP), Mallinckrodt (MNK), Radius Health (RDUS), Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX), Immuron (IMRN) and Myovant Sciences (MYOV).
Who are Syros Pharmaceuticals' key executives?
Syros Pharmaceuticals' management team includes the folowing people:
- Dr. Nancy A. Simonian, Pres, CEO & Director (Age 57)
- Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 64)
- Dr. David A. Roth M.D., Chief Medical Officer (Age 55)
- Dr. Jeremy P. Springhorn Ph.D., Chief Bus. Officer (Age 56)
- Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board
When did Syros Pharmaceuticals IPO?
(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Syros Pharmaceuticals been receiving favorable news coverage?
Media headlines about SYRS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a coverage optimism score of 0.15 on Accern's scale. They also assigned media stories about the company an impact score of 47.21 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Syros Pharmaceuticals' major shareholders?
Syros Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (5.07%), BlackRock Inc. (2.86%), JPMorgan Chase & Co. (1.15%), Candriam Luxembourg S.C.A. (0.63%), Northern Trust Corp (0.56%) and Millennium Management LLC (0.50%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Eric R Olson, Jeremy P Springhorn, Redmile Group, Llc, Richard A Young, Robert Nelsen and Srinivas Akkaraju. View Institutional Ownership Trends for Syros Pharmaceuticals.
Which major investors are selling Syros Pharmaceuticals stock?
SYRS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Colleen Elizabeth Desimone, Eric R Olson and Richard A Young. View Insider Buying and Selling for Syros Pharmaceuticals.
Which major investors are buying Syros Pharmaceuticals stock?
SYRS stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Millennium Management LLC, GSA Capital Partners LLP, Northern Trust Corp, JPMorgan Chase & Co., Schwab Charles Investment Management Inc. and The Manufacturers Life Insurance Company . Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Redmile Group, Llc, Robert Nelsen and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.
How do I buy shares of Syros Pharmaceuticals?
Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syros Pharmaceuticals' stock price today?
One share of SYRS stock can currently be purchased for approximately $11.93.
How big of a company is Syros Pharmaceuticals?
Syros Pharmaceuticals has a market capitalization of $389.64 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe.
How can I contact Syros Pharmaceuticals?
Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]
MarketBeat Community Rating for Syros Pharmaceuticals (SYRS)
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Syros Pharmaceuticals (NASDAQ:SYRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Syros Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.4286, suggesting that the stock has a possible upside of 88.00%. The high price target for SYRS is $33.00 and the low price target for SYRS is $10.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.4286 | $22.4286 | $23.8343 | $26.14 |
| Price Target Upside: | 88.00% upside | 79.86% upside | 139.54% upside | 59.00% upside |
Syros Pharmaceuticals (NASDAQ:SYRS) Consensus Price Target History
Syros Pharmaceuticals (NASDAQ:SYRS) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Syros Pharmaceuticals (NASDAQ:SYRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 27.80%
Institutional Ownership Percentage: 57.68%
Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/31/2018 | Srinivas Akkaraju | Director | Buy | 209,424 | $9.55 | $1,999,999.20 | |  |
| 12/15/2017 | Jeremy P Springhorn | Insider | Buy | 15,000 | $9.08 | $136,200.00 | | |
| 12/14/2017 | Srinivas Akkaraju | Director | Buy | 109,774 | $9.03 | $991,259.22 | | |
| 10/23/2017 | Colleen Elizabeth Desimone | Insider | Sell | 550 | $16.06 | $8,833.00 | | |
| 8/14/2017 | Richard A Young | Director | Sell | 3,282 | $22.00 | $72,204.00 | 420,101 | |
| 8/7/2017 | Eric R Olson | Insider | Sell | 2,500 | $23.59 | $58,975.00 | 2,500 | |
| 7/25/2017 | Eric R Olson | Insider | Sell | 12,500 | $21.85 | $273,125.00 | 12,500 | |
| 7/25/2017 | Richard A Young | Director | Sell | 3,282 | $22.09 | $72,499.38 | 423,383 | |
| 7/6/2016 | Redmile Group, Llc | Major Shareholder | Buy | 432,746 | $12.50 | $5,409,325.00 | | |
| 7/6/2016 | Robert Nelsen | Director | Buy | 400,000 | $12.50 | $5,000,000.00 | | |
(Data available from 1/1/2013 forward)
Syros Pharmaceuticals (NASDAQ SYRS) News Headlines
| Source: |
|
Syros Pharmaceuticals (NASDAQ:SYRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Syros Pharmaceuticals (NASDAQ SYRS) Stock Chart for Thursday, May, 24, 2018
Loading chart…
